H Hjalgrim1, M Frisch, A Ekbom, K O Kyvik, M Melbye, A Green. 1. Department of Epidemiology Research, Danish Epidemiology Science Centre, Statens Serum Institut, Copenhagen, Denmark. hhjalgrim@desc.ssi.dk
Abstract
OBJECTIVES: To study the occurrence of cancer amongst patients with diabetes mellitus (DM). DESIGN: Population based cohort study. SETTING: Denmark. SUBJECTS: Two cohorts of patients with DM were identified. One cohort comprised 1659 conscripts diagnosed with type I DM before the age of 20 years. Another cohort comprised 1499 men and women with insulin treated DM identified by means of medical prescriptions on 1 July 1973. Both cohorts were followed until the end of 1992. MAIN OUTCOME MEASURES: The relative risk of cancer in the two cohorts was estimated as the ratio of observed to expected number of cancers in the cohort (SIR). RESULTS: No unusual risk of cancer was observed amongst the conscripts (SIR 0.9, n = 13) or amongst patients with onset of DM before the age of 30 years in the prescription cohort (SIR 0.9, n = 32). Amongst those aged 30 years or more at DM onset in the prescription cohort, the overall risk of cancer did not depart from normal (SIR 1.0, n = 103), however, pancreatic cancer occurred in excess both immediately (< 1 year) (SIR 190, n = 1), and during 1-9 years after DM onset (SIR 9.0, n = 4). Similarly, the risk of non-Hodgkin's lymphoma was increased significantly (SIR 3.3, n = 6), all cases occurring more than 10 years after DM onset. CONCLUSIONS: Our data suggest that there is no unusual risk of cancer associated with type I DM. Type II DM may be the first symptom of pancreatic cancer and may be associated with an increased risk of non-Hodgkin's lymphoma.
OBJECTIVES: To study the occurrence of cancer amongst patients with diabetes mellitus (DM). DESIGN: Population based cohort study. SETTING: Denmark. SUBJECTS: Two cohorts of patients with DM were identified. One cohort comprised 1659 conscripts diagnosed with type I DM before the age of 20 years. Another cohort comprised 1499 men and women with insulin treated DM identified by means of medical prescriptions on 1 July 1973. Both cohorts were followed until the end of 1992. MAIN OUTCOME MEASURES: The relative risk of cancer in the two cohorts was estimated as the ratio of observed to expected number of cancers in the cohort (SIR). RESULTS: No unusual risk of cancer was observed amongst the conscripts (SIR 0.9, n = 13) or amongst patients with onset of DM before the age of 30 years in the prescription cohort (SIR 0.9, n = 32). Amongst those aged 30 years or more at DM onset in the prescription cohort, the overall risk of cancer did not depart from normal (SIR 1.0, n = 103), however, pancreatic cancer occurred in excess both immediately (< 1 year) (SIR 190, n = 1), and during 1-9 years after DM onset (SIR 9.0, n = 4). Similarly, the risk of non-Hodgkin's lymphoma was increased significantly (SIR 3.3, n = 6), all cases occurring more than 10 years after DM onset. CONCLUSIONS: Our data suggest that there is no unusual risk of cancer associated with type I DM. Type II DM may be the first symptom of pancreatic cancer and may be associated with an increased risk of non-Hodgkin's lymphoma.
Authors: Raheem J Paxton; Su Yon Jung; Mara Z Vitolins; Jenifer Fenton; Electra Paskett; Michael Pollak; Jennifer Hays-Grudo; Stephen D Hursting; Shine Chang Journal: Cancer Causes Control Date: 2014-09-20 Impact factor: 2.506
Authors: Michael G Schrauder; Peter A Fasching; Lothar Häberle; Michael P Lux; Claudia Rauh; Alexander Hein; Christian M Bayer; Katharina Heusinger; Arndt Hartmann; Johanna D Strehl; David L Wachter; Rüdiger Schulz-Wendtland; Boris Adamietz; Matthias W Beckmann; Christian R Loehberg Journal: J Cancer Res Clin Oncol Date: 2010-12-05 Impact factor: 4.553
Authors: Jae Moon Yoon; Ki Young Son; Chun Sick Eom; Daniel Durrance; Sang Min Park Journal: World J Gastroenterol Date: 2013-02-14 Impact factor: 5.742
Authors: Dana E Rollison; Anna R Giuliano; Thomas A Sellers; Christine Laronga; Carol Sweeney; Betsy Risendal; Kathy B Baumgartner; Tim Byers; Martha L Slattery Journal: Am J Epidemiol Date: 2007-11-21 Impact factor: 4.897